Alpaca nanobodies effective against South African SARS-CoV-2 variant

Alpaca nanobodies effective against South African SARS-CoV-2 variant

Researchers in South Africa and the UK have identified alpaca-derived nanoantibodies that potently n...
read more
New study could revive once-promising immunotherapies for treating solid tumors

New study could revive once-promising immunotherapies for treating solid tumors

New research from UVA Cancer Center could rescue o...
read more
Novel hydrogel-based vaccine formulation shows high efficacy against SARS-CoV-2

Novel hydrogel-based vaccine formulation shows high efficacy against SARS-CoV-2

A fascinating new preprint research paper posted t...
read more
COVID vaccines have only 17% detectable antibodies against SARS-CoV-2 virus

COVID vaccines have only 17% detectable antibodies against SARS-CoV-2 virus

When clinical trials were conducted to determine t...
read more
Researchers develop rapid method for identifying antibody-resistant SARS-CoV-2 mutants

Researchers develop rapid method for identifying antibody-resistant SARS-CoV-2 mutants

Researchers in the United States have described a ...
read more
Researchers show potential benefits of delaying second mRNA COVID-19 vaccine dose

Researchers show potential benefits of delaying second mRNA COVID-19 vaccine dose

The currently approved mRNA vaccines from Moderna ...
read more
Researchers examine long-term immune responses following COVID-19 across clinically diverse cohort

Researchers examine long-term immune responses following COVID-19 across clinically diverse cohort

In the light of the enormous number of cases of co...
read more
COVID-19 CG tracks local SARS-CoV-2 mutations by geographical location

COVID-19 CG tracks local SARS-CoV-2 mutations by geographical location

Genomic surveillance of acute respiratory syndrome...
read more
New SARS-CoV-2 B.1.526 variant emerges in New York

New SARS-CoV-2 B.1.526 variant emerges in New York

New York has the first case of a new severe acute ...
read more
Antibody and T cell response to SARS-CoV-2 persist up to 8 months: Study of Ski Resort Ischgl

Antibody and T cell response to SARS-CoV-2 persist up to 8 months: Study of Ski Resort Ischgl

The first instance of the severe acute respiratory...
read more